Is XRAY a buy according to AI stock analysis?

XRAY AI stock analysis does not label DENTSPLY SIRONA a universal buy because the dental equipment leader has strong brands and recurring revenue but also carries high debt leverage, negative GAAP equity, competitive pressure in digital dentistry, and a restructuring whose outcome is uncertain. A rules-based investor would compare the $12.26 price with forward EPS estimates, debt reduction progress, restructuring milestones, and the scenario range before making a decision.

What is the XRAY AI stock forecast?

The XRAY AI stock forecast uses scenarios, not a guaranteed price prediction. The current framework points to a bearish area near $5 to $9, a base area near $13 to $17, and a bullish area near $25 to $30 over three years before capital returns, depending on dental demand recovery, restructuring execution, debt reduction, and valuation multiple.

What technical levels matter for XRAY?

The technical levels that matter for XRAY are support near $11.00 to $11.50, deeper trend support at the $9.40 52-week low, and resistance near $12.50 to $13.00 with the 200-day moving average near $13.80 as the key trend change level. These levels come from the July 10, 2026 technical snapshot and should be refreshed with live chart data before trading.

Can AI predict XRAY stock price?

No, AI cannot reliably predict stock prices. It can organize XRAY filings, valuation math, technical levels, and risk scenarios, but future XRAY returns can still be changed by dental demand, restructuring execution, competitive dynamics, debt refinancing, interest rates, and investor sentiment.

How should I use this XRAY AI trading strategy?

Use this XRAY AI trading strategy as a research checklist, not personal financial advice. Pair the trend-following and mean-reversion setups with live quotes, position sizing, earnings dates, debt updates, restructuring news, and your own risk limits.

What is the main risk for XRAY investors?

The main risk for XRAY investors is the balance sheet. With a 178% debt-to-equity ratio and negative GAAP equity, DENTSPLY SIRONA has limited financial flexibility. A sustained downturn in dental demand, failure to restructure profitably, or rising interest rates could force asset sales or equity dilution that would significantly impair shareholder value.

DENTSPLY SIRONA Inc. research snapshot

XRAY AI Stock Analysis

XRAY AI stock analysis reads DENTSPLY SIRONA as a global dental equipment, consumables, and technology company facing a post-pandemic demand reset, large impairment charges, high debt leverage, and a fundamental restructuring story. At the July 10, 2026 data cutoff, XRAY traded near $12.26 with an independently verified market capitalization of about $2.46 billion. The stock has a forward P/E of 7.52x, a 5% dividend yield, and analyst consensus Hold with a $13.55 average target. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.

Current price

$12.26

Market cap

$2.46 billion

AI score

55 / 100

Rating

Dental equipment leader with restructuring, debt, and GAAP loss overhang

Trend status

Recovering from multi-year lows with high short interest

Data cutoff (updated weekly)

July 10, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. DENTSPLY SIRONA has long SEC filing history, quarterly earnings reports, segment disclosures, analyst coverage from 13 firms, and market data, but GAAP losses from impairment charges and restructuring obscure underlying operating trends.
bias Check: The main AI bias risk is extrapolating recent price recovery as a turnaround signal while under-weighting the structural debt burden, negative GAAP equity, competitive pressure in clear aligners from Align Technology, and dental procedure volume uncertainty.
ai Confidence: High for reported revenue, cash, debt, share count, market cap math, and technical snapshots. Medium for forward scenarios because earnings depend on dental demand recovery, restructuring execution, debt reduction, and competitive dynamics in digital dentistry.
investment Certainty: Low to medium. DENTSPLY SIRONA has established brands and global distribution scale, but actual investment certainty depends on whether management can stabilize margins, reduce debt, and return to GAAP profitability without further dilution.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	DENTSPLY SIRONA is a top-tier dental equipment manufacturer with leading positions in imaging (CBCT/CEREC), consumables (endodontics, restorative), orthodontics (SureSmile), and specialty urology (Wellspect). The business generates recurring consumable and service revenue but has been disrupted by digital competition and post-COVID demand normalization.	Medium
Moat	The moat comes from installed base of equipment (CEREC, imaging), brand trust in endodontics and restorative, global distribution network, regulatory approvals, and R&D. The moat has narrowed as digital dentistry (intraoral scanners, 3D printing, clear aligners) becomes more competitive and Align Technology and 3D Systems encroach on traditional territory.	Medium
Management	CEO Simon Campion (2022-2026) led the restructuring and was replaced by Daniel Scavilla. The new CFO John Fortson was appointed in June 2026. Management credibility is mixed after years of impairment charges, goodwill writedowns, and a debt-heavy balance sheet that limits strategic flexibility.	Low-medium
Financial trend	TTM revenue is approximately $3.68 billion with GAAP net income of -$628 million largely driven by non-cash impairment and restructuring charges. Q1 2026 revenue was $880 million with adjusted EPS of $0.27. Operating income trends show stabilization but the debt load and interest expense consume significant cash flow.	High
Valuation	At $12.26, XRAY trades at 7.52x forward EPS estimates, 0.58x price/sales, 1.61x book value, and an 18.86x P/FCF on levered free cash flow. The three-year scenario framework suggests a bearish area near $7, a base area near $15, and a bullish area near $30, assuming normalized earnings recovery.	Medium
Technical trend	XRAY has recovered from its 52-week low of $9.40 and is trading near $12.26. The stock is between short and long-term moving averages after a multi-year downtrend. High short interest suggests potential squeeze dynamics but also reflects fundamental skepticism.	Medium
Risk level	Key risks are high debt leverage (178% D/E), negative GAAP equity, competitive pressure in clear aligners and digital dentistry, dental procedure volume sensitivity to consumer spending, debt covenant compliance, and potential equity dilution if refinancing requires capital raises.	Medium-high
AI confidence	High for descriptive research, market data, and ratio calculations. Lower for turnaround probability because the restructuring outcome depends on execution factors that public data cannot fully capture.	Medium
Investment certainty	Low certainty. The business has real assets and global reach, but the debt load, competitive threats, and GAAP loss overhang create a wide range of outcomes. A margin of safety would require the stock to price in significant restructuring failure risk.	Low

XRAY AI stock forecast

XRAY AI Stock Forecast Scenarios

The XRAY AI stock forecast uses scenario math around the $12.26 quote and a forward EPS estimate of about $1.63 per analyst consensus. The three-year framework produced a bearish area near $7, a base area near $15, and a bullish area near $30. The wide range reflects the gap between turn-around potential and balance-sheet risk.

Bullish case

$25 to $30

More likely if dental demand recovers strongly, restructuring generates measurable margin improvement, debt is reduced, GAAP profitability returns, and the market values normalized earnings near 12x.

Base case

$13 to $17

More likely if EPS compounds near 5% annually, restructuring stabilizes margins, debt remains manageable, and investors value XRAY near 8x forward earnings. The analyst average target of $13.55 sits inside this range.

Bearish case

$5 to $9

More likely if dental demand weakens further, competitive pressure in digital dentistry and clear aligners intensifies, debt covenants tighten, and the market values earnings near 5x or lower.

XRAY AI technical analysis

XRAY AI Technical Analysis

XRAY AI technical analysis is cautiously constructive after a 30% recovery from the $9.40 52-week low but remains in a long-term downtrend. At the July 10, 2026 cutoff, price was near $12.26. Technical levels should be refreshed with live chart data before trading.

Level	Value	Why it matters
Current price	$12.26	July 10, 2026 closing quote used for market cap and valuation math at the data cutoff.
Near support	$11.00 to $11.50	Recent pullback support area. A hold above this band keeps the short-term recovery intact.
Deeper support	$9.40 to $10.00	The 52-week low area is the ultimate support reference. A break below would signal trend resumption to the downside.
Near resistance	$12.50 to $13.00	The stock needs to clear this zone to confirm the recovery has room to run toward analyst targets.
Upper resistance	$14.00 to $15.00	The 200-day moving average likely sits in this zone. A breakout above would be a meaningful trend change signal.
50-day moving average	Approximately $11.40	Price was above this short-term trend gauge, supporting the current recovery.
200-day moving average	Approximately $13.80	Price was below this long-term trend gauge, confirming the broader downtrend is still in play.
Momentum	Neutral-to-bullish short term	Recovery from lows has been strong, but momentum needs follow-through above $13 to become sustainably bullish.
Volume	About 5 million average daily shares	Elevated volume during the recovery suggests genuine buying interest rather than low-volume drift.
Volatility	Dental demand and restructuring-driven	XRAY volatility can spike around earnings, debt news, restructuring updates, and competitor announcements.
Invalidation	Close below $11, then $9.40	A close below $11 would weaken the recovery setup. A new low below $9.40 would suggest the restructuring story is not gaining traction.

XRAY AI trading strategy

XRAY AI Trading Strategy Framework

The XRAY AI trading strategy is a rules-based research framework for a dental equipment company in restructuring with high debt leverage and potential for significant price swings. It is not personal advice and should be paired with live quotes, filings, position sizing, and risk controls.

Trend-following setup

Wait for XRAY to hold above the 50-day moving average near $11.40 and clear resistance at $12.50 to $13.00 with volume confirmation, improving earnings estimates, and no adverse debt or competitive news.

A close below $11.00 or a failed breakout after earnings should invalidate the short-term setup.

Mean-reversion setup

If XRAY pulls back toward the $9.40 to $10.00 support band without a fundamental surprise, compare the price with debt levels, cash flow, restructuring milestones, and competitive dynamics.

Do not average down below $10 without a defined loss limit because high leverage and negative GAAP equity increase bankruptcy risk for a sustained downturn.

Fundamental monitor

Track revenue by segment (Connected Tech, Essential Dental, Ortho/Implant, Wellspect), adjusted operating margin, free cash flow, debt-to-EBITDA, interest coverage, restructuring charges, debt covenant headroom, and insider buying.

Reduce confidence if debt reduction stalls, free cash flow turns negative, adjusted margins compress, or the company signals a need for equity financing.

Investment research summary

Four-master Research Compression

Business essence

DENTSPLY SIRONA sells dental equipment (imaging, CAD/CAM, handpieces), consumables (endodontics, restorative, anesthetics), orthodontic solutions (SureSmile clear aligners), implants, and specialty urology catheters to dentists, labs, and hospitals globally. Customers pay for brand trust, installed base compatibility, distribution breadth, and clinical support.

Moat

The moat rests on installed equipment base, brand heritage (over 140 years), regulatory approvals, global rep network, and R&D in digital dentistry. It has narrowed due to competition from Align Technology in clear aligners, 3D printing alternatives in digital workflow, and smaller nimble competitors in segments like intraoral scanning.

Munger risk inversion

The thesis fails if restructuring cannot restore GAAP profitability, debt becomes unsustainable and forces equity dilution or asset sales, competitive losses in clear aligners and digital dentistry accelerate, or dental procedure volumes decline due to consumer spending weakness.

Management

Simon Campion was brought in from BD in 2022 to lead a restructuring that has been slower than expected. The recent CEO change to Daniel Scavilla and CFO appointment of John Fortson signal a potential strategy reset. Capital allocation credibility needs rebuilding after years of goodwill impairment and leverage buildup.

Industry trend

Dentistry benefits from aging demographics and increasing cosmetic awareness globally. Digital transformation (intraoral scanning, CAD/CAM, 3D printing, AI diagnostics) creates both opportunity and disruption. The industry is not recession-proof but tends to be more stable than elective medical procedures.

Valuation and margin of safety

XRAY looks optically cheap on forward P/E and price/sales, but the balance sheet carries significant debt with negative GAAP equity. Margin of safety depends on whether normalized earnings materialize, debt is paid down, and the company avoids equity dilution. The current price appears to discount some restructuring success without fully pricing in the downside risk.

Source-backed data

XRAY Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
XRAY price	$12.26 reference close on July 10, 2026	Google Finance market data	July 10, 2026
Market capitalization	$2.46 billion, verified as $12.26 x 200.33 million shares with 0.00% variance	financial_rigor.py market cap verification	July 10, 2026
Shares outstanding	200.33 million shares	Google Finance and Yahoo Finance cross-check	July 10, 2026
TTM revenue	Approximately $3.68 billion	Yahoo Finance and Google Finance quarterly data	July 10, 2026
TTM GAAP net income	-$628 million (includes impairment and restructuring charges)	Yahoo Finance income statement	July 10, 2026
Q1 2026 adjusted EPS	$0.27 adjusted diluted EPS	Google Finance earnings data	July 10, 2026
Forward EPS estimate	Approximately $1.63 per analyst consensus	Yahoo Finance and Google Finance forward estimates	July 10, 2026
Cash and debt	$190 million cash; debt-to-equity ratio 177.79%, with significant goodwill and intangible assets on the balance sheet	Yahoo Finance key statistics	July 10, 2026
Valuation snapshot	7.52x forward P/E, 0.58x price/sales, 1.61x book value, 18.86x P/FCF, 5.22% FCF yield, 5.04% dividend yield	financial_rigor.py valuation verification and Yahoo Finance	July 10, 2026
Technical snapshot	Recovery above $12 from $9.40 52-week low, below 200-day moving average near $13.80	Google Finance price data and TradingView	July 10, 2026

Frequently Asked Questions

Read the HSIC AI stock analysis View ALGN AI stock forecast Explore BDX AI technical analysis Compare BA healthcare analysis Open the AI Stock Picker Build an AI trading strategy Screen U.S. stocks Analyze chart setups

This XRAY AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios are based on available public data as of July 10, 2026 and may be wrong if DENTSPLY SIRONA fundamentals, dental demand, restructuring results, debt costs, competitive dynamics, interest rates, regulation, or market valuation change.